Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
STI Biotechnologie is a French biotechnology company specializing in the development and production of probiotic-based solutions for animal nutrition and health. Founded in 2007, the company leverages its expertise in lactic acid bacteria fermentation to create additives that improve digestive efficiency and immune resilience in livestock, including cattle, swine, and poultry. Its core product lines, such as the Stimul’ range, utilize specific strains like Lactobacillus farciminis to optimize the gut microbiome. In 2020, STI Biotechnologie was acquired by Idena, a subsidiary of the Avril Group, to strengthen its portfolio in natural alternatives to antibiotics.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on STI Biotechnologie.